Sunshine Biopharma (SBFM) news

Corrected-Sunshine Biopharma (not 'Health Canada'): Approves Sunshine Biopharma's atenolol for treating and managing cardiovascular conditions

Sunshine Biopharma Inc. (NASDAQ:SBFM) announced on August 31, 2026, that it has received regulatory approval for its Atenolol tablets in 25mg, 50mg, and 100mg strengths for the Canadian market. Atenolol is a beta-blocker used to manage hypertension, angina pectoris, and post-myocardial infarction…

Health Canada: Approves Sunshine Biopharma's atenolol for treating and managing cardiovascular conditions

Sunshine Biopharma: Enalapril expected to begin shipping to Canadian pharmacies by year-end 2026

Sunshine Biopharma Inc. (NASDAQ:SBFM) is preparing to expand its portfolio of generic prescription medications with the anticipated launch of Enalapril in the Canadian market by the end of 2026. Enalapril, an angiotensin-converting enzyme (ACE) inhibitor, is commonly prescribed for the treatment of…

Sunshine Biopharma: receives Canadian regulatory approval for enalapril

Sunshine Biopharma Inc. (NASDAQ: SBFM) has announced that it has received Canadian regulatory approval for its generic formulation of enalapril, a widely used angiotensin-converting enzyme (ACE) inhibitor. Enalapril is prescribed to manage hypertension and heart failure and is also used…

Sunshine Biopharma enters at-the-market sales agreement with Aegis Capital for up to $4 mln - SEC filing

Sunshine Biopharma Inc. (NASDAQ: SBFM) has announced the initiation of an at-the-market (ATM) equity offering through Aegis Capital Corp., its sole placement agent, with the goal of raising up to $6 million. The offering includes the sale of up to 5,825,242 common units, each consisting of one…